Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Case-finding Study to Detect and Quantify Episodes of Absolute Arrhythmia Using an Automated, Wearable Monitoring System (Smart in OAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04579159
Recruitment Status : Recruiting
First Posted : October 8, 2020
Last Update Posted : March 8, 2021
Sponsor:
Collaborators:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Preventicus GmbH
Corsano/ MMT
Getemed Medizin- und Informationstechnik
Information provided by (Responsible Party):
Atrial Fibrillation Network

Brief Summary:
This feasibility study will develop and evaluate pathways to identify participants with wearable-detected absoulute Arrhythmia (AA) and to enable local study teams to contact them regarding participation in a controlled trial of oral anticoagulation in this population, which will be conducted after the feasibility study.

Condition or disease Intervention/treatment Phase
Atrial Arrhythmia Device: Preventicus heartbeat app in combination with wearables Not Applicable

Detailed Description:
In this study, the feasibility of evaluating the efficacy of a cloud based analytic service in combination with a PPG-wearable in detecting AA will be assessed and the number of cases found. The design aims to provide simple, low-threshold access to this screening technology targeting at-risk populations. This study will not cause any restrictions on the usual care of the study participants. Access to the screening will be provided close to home and free of charge. The app will also be used to validate and enhance the clinical information about the participants captured during the study. This information will be used to define and refine target groups with highest screening efficiency and, in the long-term, outcome benefits. The study will describe the prevalence of AA in an unselected population that can be reached by a low-threshold screening procedure. The study will also generate important information on the different possible screening environments in different countries (e.g. pharmacies, GP practices, etc). Structures of work-up and continuous patient management in screen-positive individuals will be described and may help to design screening pathways in the main trial. By verifying the wearable-diagnoses by ECG in all screen-positive and a random selection of screen-negative participants, the diagnostic accuracy of the wearable in combination of cloud based analytic service can be estimated. Cost effectiveness assessment will evaluate the cost of low-threshold remote screening per patient identified and help guide to target high risk groups with optimal screening yield in the future. The collected data will provide the sound basis for the design and conduct of a large outcome trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2000 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Multicentre, Intern., Inv.-Initiated, Single-arm Case-finding Study of a Cloud Based Analytic Service as Screening Tool to Detect and Quantify Episodes of Absolute Arrhythmia Using an Automated, Wearable PPG-based Monitoring System
Actual Study Start Date : January 26, 2021
Estimated Primary Completion Date : January 31, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Arrhythmia

Arm Intervention/treatment
only control group
To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
Device: Preventicus heartbeat app in combination with wearables
CE certified devices




Primary Outcome Measures :
  1. Prevalence of AA measured as number of participants with AA detected by the wearable in relation to all included participants [ Time Frame: Screening per participant: 8 weeks ]
    Prevalence of AA measured as number of participants with AA detected by the wearable in relation to all included participants


Secondary Outcome Measures :
  1. Rate of participants with newly detected Atrial Arrhythmia [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Rate of participants with newly detected Atrial Arrhythmia by the wearable

  2. Proportion of participants with AA contacting the study centre [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Proportion of participants with AA contacting the study centre in relation to all participants with detected AA

  3. Number of participants wearing the 14 day Tele ECG patch after detection of AA [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Number of participants wearing the 14 day Tele ECG patch after detection of AA by the wearable

  4. Number of participants enrolled per day/week [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Number of participants enrolled per day/week

  5. Number of participants with arrhythmias (sub-analysis: AF) confirmed by 14 day Tele ECG [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Number of participants with arrhythmias (sub-analysis: AF) confirmed by 14 day Tele ECG

  6. Sensitivity and specificity regarding the diagnosis of arrhythmia [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Sensitivity and specificity regarding the diagnosis of arrhythmia in subgroup of participants with and without wearable-detected Atrial Arrhythmia with ECG-confirmed diagnosis

  7. Duration: The duration from start of measurement to the first positive screening result and from the start of the 14 day Tele ECG to the first episode of AF [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Duration: The duration from start of measurement to the first positive screening result technically verified by Telecare and from the start of the 14 day Tele ECG to the first episode of AF verified by Telecare

  8. Geographical effects: Regional differences of AA prevalence (diagnostic yield) and differences by screening route [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Geographical effects: Regional differences of AA prevalence (diagnostic yield) and differences by screening route

  9. Compliance of participants using the app/wearable: percentage of active users after two weeks [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Compliance of participants using the app/wearable: percentage of active users after two weeks assessed by Telecare

  10. Duration of AA episodes and AA burden (time in AA / monitored time) verified by Telecare [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Duration of AA episodes and AA burden (time in AA / monitored time) verified by Telecare

  11. EQ-5D-5L visual analogue scale [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    EQ-5D-5L visual analogue scale: Qualtiy of life measured by the scale

  12. Recommendation for change in medication [ Time Frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months ]
    Recommendation for change in medication after ECG screening



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Inclusion criteria:

  • 65 years or older
  • Willing and able to provide informed consent
  • Owning mobile phone compatible with the PPG-wearable

Exclusion criteria:

  • Known AF
  • Known current or planned oral anticoagulation treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04579159


Contacts
Layout table for location contacts
Contact: Emilia Czarnecki +49 (0)251-980-1340 emilia.czarnecki@af-net.eu
Contact: Alexandra Simbrich +49 (0)251-980-1345 alexandra.simbrich@af-net.eu

Locations
Layout table for location information
Germany
Universitäres Herz- und Gefäßzentrum UKE Hamburg Not yet recruiting
Hamburg, Germany
Contact: Simone Neumann       si.neumann@uke.de   
Principal Investigator: Renate Schnabel         
Poland
Krakowskie Centrum Diagnostyczno-Kliniczne (KCDK) Recruiting
Kraków, Poland, 31-514
Contact: Klaudia Proniewska       afnet@kcdk.pl   
Principal Investigator: Dariusz Dudek         
Sponsors and Collaborators
Atrial Fibrillation Network
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Preventicus GmbH
Corsano/ MMT
Getemed Medizin- und Informationstechnik
Investigators
Layout table for investigator information
Principal Investigator: Larissa Fabritz, Professor Institute of Cardiovascular Sciences, University of Birmingham
Layout table for additonal information
Responsible Party: Atrial Fibrillation Network
ClinicalTrials.gov Identifier: NCT04579159    
Other Study ID Numbers: Smart in OAC - AFNET 9
First Posted: October 8, 2020    Key Record Dates
Last Update Posted: March 8, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes